Precision Biologics, Inc. declared in vivo and in vitro efficacy of its novel tumor-specific ADC (PB-vcMMAE-5) in competition against human carcinomas reacting with truncated core 2 O-glycans. The current data for various human cancer types, précising truncated core 2 O-glycans, will be out in a poster format at the Society for Immunotherapy of Cancer (SITC) Annual Meeting at National Harbor, MD, USA, on 7th November 2025.
The poster title will be ‘In vitro and in vivo efficacy of the antibody-drug-conjugate (ADC) PB-vcMMAE-5 against human carcinoma expressing truncated core 2 O-glycans.’ The presentation will be made under a primary category ‘Immuno-Conjugates and Chimeric Molecules’, made in person on 7th November 2025, around 12:15 pm – 1:45 pm ET, and 5:35 pm – 7 pm ET.
The PB-vcMMAE-5’s in vitro efficacy against various human cancer cell lines involves examination of the in vitro cytotoxicity of PB-vc-MMAE-5 in 9 human cancer cell lines, consisting of other conditions and combinations. The PB-223 binds particularly to human tumor tissues, avoiding human normal tissue. The PB-223 showed a potent reaction with lung, ovarian, prostate, pancreatic and colorectal tumor tissues. The study also highlighted that PB-vcMMAE-5 eliminated all cell lines tested, with the peak percentage of discarding identified against MDA-MB-231, OV-90, NCI-H226 and LnCAP cancer cell lines.
In complementary, the plain PB-223 mAb didn’t eliminate any cell lines tested. In vivo safety of PB-vcMMAE-5 in NOD-SCID mice holding OV-90 xenografts were given weekly doses of PB-vcMMAE-5 or PBS, MMAE alone for a straight five weeks. The animal body weight was measured and observed twice a week regularly as an indirect calculation of toxicity. The status of mice and the days calculation from the first ADC infusion have been mentioned in the data.
The in vivo efficacy of PB-vcMMAE-5 in mice showed the efficacy of the ADC PB-vcMMAE-5 that was examined in the OV-90 subcutaneous xenograft model developed in NOD-SCID mice. The data mentioned in this study highlighted that PB-vcMMAE-5 persuaded prominent tumor growth inhibition in comparison to the control in a dose-dependent manner.
The findings reveal the potential of the PB-vcMMAE-5, showing PB-223’s focus is disturbing in in vivo mice and can kill human cancer cells. The poster recalls the PB-vcMMAE-5’s stability in human plasma. The data claims that PB-vcMMAE-5 is capable enough as a best therapeutic option for several human malignancies presenting core 2 O-glycans.
Mansi Kadam is a market research writer with over 3 years of experience analyzing trends in the healthcare industry. At Towards Healthcare, she covers innovations in medical sector, sustainability initiatives, and the evolving regulatory landscape.
